US 12,467,053 B2
Hybrid immunoglobulins with moving parts
Daniel Capon, Hillsborough, CA (US)
Assigned to BIOMOLECULAR HOLDINGS LLC, Burlingame, CA (US)
Filed by Daniel Capon, Hillsborough, CA (US)
Filed on Oct. 1, 2019, as Appl. No. 16/590,143.
Application 16/590,143 is a continuation of application No. 15/198,475, filed on Jun. 30, 2016, granted, now 10,428,332.
Application 15/198,475 is a continuation of application No. 11/982,085, filed on Oct. 31, 2007, abandoned.
Claims priority of provisional application 60/856,864, filed on Nov. 2, 2006.
Prior Publication US 2020/0032272 A1, Jan. 30, 2020
Int. Cl. C07K 1/00 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); C12N 15/62 (2006.01)
CPC C12N 15/625 (2013.01) [A61K 47/6835 (2017.08); A61K 47/6875 (2017.08); A61K 51/1084 (2013.01); C12N 15/62 (2013.01); C07K 2317/52 (2013.01); C07K 2319/30 (2013.01)] 6 Claims
 
1. A chimeric polypeptide consisting of, from its N-terminus to C-terminus:
a. a human IgG Fc polypeptide beginning with the sequence selected from the group consisting of CDKTHTCPPCP (residues 1-11 of SEQ ID NO:35), CCVECPPCP (residues 1-9 of SEQ ID NO:53), CPRCP (residues 1-5 of SEQ ID NO:74), CPSCP (residues 1-5 of SEQ ID NO:89), CPPCP (residues 1-5 of SEQ ID NO:104), or CP (residues 1-2 of SEQ ID NO:112), joined at its C-terminus by a peptide bond to
b. the N-terminus of the polypeptide encoded by a human IgG M1 exon or a portion of the polypeptide encoded by a human IgG M1 exon, having a C-terminal X-terminus wherein: (a) the polypeptide encoded by the human IgG M1 exon having a C-terminal X-terminus consists of the sequence ELQLEESCAEAQDGELDGX (residues 227 to 245 of SEQ ID NO: 138) wherein X is a cysteine, homocysteine, selenocysteine, or homoselenocysteine, or (b) the portion of the polypeptide encoded by the human IgG M1 exon having a C-terminal X-terminus consists of the sequence ELQLEESC (residues 221 to 228 of SEQ ID NO: 135).